Is oncoplastic breast conserving surgery oncologically safe? A meta-analysis of 18,103 patients

Am J Surg. 2020 Aug;220(2):385-392. doi: 10.1016/j.amjsurg.2019.12.019. Epub 2020 Jan 2.

Abstract

Background: Oncoplastic Breast Conserving Surgery (OBCS) allows adequate resection margins of tumours unsuitable for standard breast conserving surgery (SBCS) whilst allowing for better cosmesis and reduced morbidity when compared to mastectomy. However, there is limited evidence on its oncological safety.

Methods: This study aims to compare oncological safety of OBCS with SBCS and mastectomy by examining the relative risk of cancer recurrence and re-operation rates through meta-analysis.

Results: 18 studies met the search criteria including 18,103 patients. The primary outcome measure (recurrence) was not significantly different between OBCS and SBCS or mastectomy (RR 0.861; 95% CI 0.640-1.160; p = 0.296). The secondary outcome measure (re-operation) initially achieved significance in favour of OBCS (RR 0.64; 95% CI 0.46-0.89; p = 0.01). However, after adjustment for publication bias this was attenuated to insignificance between the two study groups (RR 0.86; 95% CI 0.56-1.31; p = 0.44).

Conclusions: For both cancer recurrence and re-operation rate, there was no significant difference between OBCS and traditional techniques. OBCS is of comparable oncological safety to more established surgical procedures and a useful option in suitable patients.

Keywords: Oncoplastic breast conserving surgery; Oncoplastic surgery; Oncoplasty; Therapeutic mammaplasty; Therapeutic mammoplasty.

Publication types

  • Meta-Analysis

MeSH terms

  • Breast Neoplasms / surgery*
  • Female
  • Humans
  • Mastectomy, Segmental / adverse effects*